Skip to main content
Log in

High-flow nasal cannula cost effective in chronic respiratory failure

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Notes

  1. 2019 British pounds

Reference

  • Sorensen SS, et al. Cost-Effectiveness of Domiciliary High Flow Nasal Cannula Treatment in COPD Patients with Chronic Respiratory Failure ClinicoEconomics and Outcomes Research 2021: 553-564, No. 13, 18 Jun 2021. Available from: URL: http://doi.org/10.2147/CEOR.S312523

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

High-flow nasal cannula cost effective in chronic respiratory failure. PharmacoEcon Outcomes News 882, 15 (2021). https://doi.org/10.1007/s40274-021-7849-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-7849-y

Navigation